{"Literature Review": "Biased agonism represents a paradigm shift in pharmacology, offering the potential to design drugs that selectively activate therapeutic signaling pathways while minimizing adverse effects. This concept has been particularly explored in the context of opioid receptors, where the distinction between G protein– and β-arrestin–dependent signaling pathways has been a focal point of research. The initial hypothesis posited that μ-opioid receptor agonists favoring G protein over β-arrestin signaling could provide effective analgesia without the associated risks of respiratory depression and other adverse effects (DeWire et al., 2013). This hypothesis was supported by early studies demonstrating that β-arrestin–2 knockout mice exhibited enhanced morphine-induced analgesia with reduced respiratory depression and constipation (Raehal et al., 2005). However, the landscape of biased agonism at the μ-opioid receptor has become increasingly complex with emerging data challenging the initial assumptions. Recent studies have revealed that both the therapeutic and adverse effects of μ-opioid receptor activation are predominantly mediated through G protein–dependent signaling pathways, suggesting that the separation of these effects based on signaling bias may not be as straightforward as once thought (Manglik et al., 2016). Furthermore, the characterization of certain drugs as G protein biased has been called into question, with evidence suggesting that these compounds may instead act as low-intrinsic-efficacy agonists rather than true biased agonists (Gillis et al., 2020). This reevaluation underscores the importance of rigorous pharmacological characterization in the study of biased agonism. Beyond the μ-opioid receptor, biased agonism has also been explored at other opioid receptor subtypes, including the δ- and κ-opioid receptors, where distinct signaling biases have been associated with unique physiological outcomes (Pradhan et al., 2010). For instance, δ-opioid receptor agonists biased towards G protein signaling have been shown to produce antinociception without the development of tolerance, while κ-opioid receptor agonists biased towards β-arrestin signaling have been linked to dysphoria and stress responses (Brust et al., 2016). These findings highlight the potential of biased agonism to refine opioid pharmacology, but also emphasize the need for a nuanced understanding of receptor signaling dynamics. The development of biased ligands for opioid receptors has been facilitated by advances in structural biology and computational modeling, which have provided insights into the molecular mechanisms underlying biased signaling (Che et al., 2018). Additionally, the use of novel assay systems and analytical frameworks has improved the ability to detect and quantify biased agonism, enabling more precise pharmacological profiling (Kenakin et al., 2012). Despite these advancements, challenges remain in translating biased agonism from bench to bedside, including the need for improved predictive models of in vivo efficacy and safety, as well as the development of biased ligands with optimal pharmacokinetic and pharmacodynamic properties (Violin et al., 2014). In conclusion, the study of biased agonism at opioid receptors has provided valuable lessons on the complexity of receptor signaling and the potential for therapeutic innovation. While the initial promise of G protein–biased μ-opioid receptor agonists has been tempered by recent findings, the exploration of biased agonism continues to offer opportunities for the development of safer and more effective opioid analgesics. Future research in this field will benefit from a multidisciplinary approach, integrating insights from pharmacology, structural biology, and systems biology to unravel the intricacies of biased signaling and its therapeutic implications.", "References": [{"title": "A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine", "authors": "DeWire, Scott M., Yamashita, Dennis S., Rominger, David H., Liu, Guodong, Cowan, Conrad L., Graczyk, Thomas M., Chen, Xiao-Tao, Pitis, Philip M., Gotchev, Dimitar, Yuan, Catherine, Koblish, Michael, Lark, Michael W., Violin, Jonathan D.", "journal": "Journal of Pharmacology and Experimental Therapeutics", "year": "2013", "volumes": "344", "first page": "708", "last page": "717", "DOI": "10.1124/jpet.112.201616"}, {"title": "Morphine side effects in β-arrestin 2 knockout mice", "authors": "Raehal, Kirsten M., Bohn, Laura M.", "journal": "Journal of Pharmacology and Experimental Therapeutics", "year": "2005", "volumes": "314", "first page": "1195", "last page": "1201", "DOI": "10.1124/jpet.105.087254"}, {"title": "Structure-based discovery of opioid analgesics with reduced side effects", "authors": "Manglik, Aashish, Lin, Henry, Aryal, Dipendra K., McCorvy, John D., Dengler, Daniela, Corder, Gregory, Levit, Anat, Kling, Ralf C., Bernat, Viachaslau, Hübner, Harald, Huang, Xi-Ping, Sassano, Maria F., Giguère, Patrick M., Löber, Stefan, Da Duan, Grutter, Thomas, Kroeze, Wesley K., Che, Tao, Nagase, Hiroshi, Carroll, F. Ivy, Jin, Jian, Shoichet, Brian K., Roth, Bryan L.", "journal": "Nature", "year": "2016", "volumes": "537", "first page": "185", "last page": "190", "DOI": "10.1038/nature19112"}, {"title": "Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists", "authors": "Gillis, Alexander, Gondin, Ana B., Kliewer, Andrea, Sanchez, Jesus, Lim, Herman D., Alamein, Christine, Manandhar, Prashant, Santiago, Marcel, Fritzwanker, Sebastian, Schmiedel, Franziska, Katte, Timo A., Reekie, Tristan A., Grimsey, Natasha L., Kassiou, Michael, Kellam, Barrie, Krasel, Cornelius, Halls, Michelle L., Connor, Mark, Lane, J. Robert, Schulz, Stefan, Canals, Meritxell.", "journal": "Science Signaling", "year": "2020", "volumes": "13", "first page": "eaaz3140", "last page": "", "DOI": "10.1126/scisignal.aaz3140"}, {"title": "Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers", "authors": "Pradhan, Amynah A., Smith, Monique L., Kieffer, Brigitte L., Evans, Christopher J.", "journal": "Pain", "year": "2010", "volumes": "151", "first page": "22", "last page": "31", "DOI": "10.1016/j.pain.2010.04.021"}, {"title": "Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria", "authors": "Brust, Torsten F., Morgenweck, Jenny, Kim, Susy A., Rose, Jamie H., Locke, Jennifer L., Schmid, Cullen L., Zhou, Lei, Stahl, Edward L., Cameron, Michael D., Scarry, Sarah M., Aube, Jeffrey, Jones, Sara R., Martin, Thomas J., Bohn, Laura M.", "journal": "Science Signaling", "year": "2016", "volumes": "9", "first page": "ra117", "last page": "", "DOI": "10.1126/scisignal.aai8441"}, {"title": "Structure of the nanobody-stabilized active state of the kappa opioid receptor", "authors": "Che, Tao, Majumdar, Susruta, Zaidi, Saheem A., Ondachi, Pauline, McCorvy, John D., Wang, Sheng, Mosier, Philip D., Uprety, Rajendra, Vardy, Eyal, Krumm, Brian E., Han, Gye Won, Lee, Ming-Yue, Pardon, Els, Steyaert, Jan, Huang, Xi-Ping, Strachan, Ryan T., Tribo, Alexandra R., Pasternak, Gavril W., Carroll, F. Ivy, Stevens, Raymond C., Cherezov, Vadim, Katritch, Vsevolod, Wacker, Daniel, Roth, Bryan L.", "journal": "Cell", "year": "2018", "volumes": "172", "first page": "55", "last page": "67", "DOI": "10.1016/j.cell.2017.12.011"}, {"title": "A scale of agonism and allosteric modulation for assessment of selectivity, bias, and receptor mutation", "authors": "Kenakin, Terry, Watson, Christian, Muniz-Medina, Vanessa, Christopoulos, Arthur, Novick, Steven.", "journal": "Molecular Pharmacology", "year": "2012", "volumes": "82", "first page": "97", "last page": "104", "DOI": "10.1124/mol.112.079509"}, {"title": "Biased ligands at G-protein-coupled receptors: promise and progress", "authors": "Violin, Jonathan D., Crombie, Aimee L., Soergel, David G., Lark, Michael W.", "journal": "Trends in Pharmacological Sciences", "year": "2014", "volumes": "35", "first page": "308", "last page": "316", "DOI": "10.1016/j.tips.2014.04.007"}]}